Everything below concerns animal model. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
| Property | Value | Notes |
|---|---|---|
| Origin | Fragment of a protein found in human gastric juice | Sequence corresponds to a fifteen-residue portion of the parent protein |
| Sequence | GEPPPGKPADDAGLV | Single linear chain, fifteen amino acids |
| Reported molecular weight | About 1419 daltons | Value quoted consistently in supplier and review literature |
| Regulatory status | Not an approved human medicine in the US or EU | Handled and sold as a research chemical |
| Sports status | Listed as prohibited | Falls under non-approved-substance categories in anti-doping codes |
Standard practice for the solid form is storage at minus twenty degrees Celsius or colder, kept dry and away from light. Containers are usually sealed with a desiccant to limit moisture uptake. Reconstituted solutions are typically held at two to eight degrees Celsius and used within a short window, because potency can decline over days to weeks depending on the buffer and concentration. Freezing an already dissolved sample may help, though repeated thawing is discouraged. Specific shelf-life claims vary between suppliers and are rarely supported by published stability studies.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength that captures the peptide backbone. The main peak area is reported as a percentage of total peak area, which serves as a conventional purity figure. Mass spectrometry provides an independent check on molecular mass and helps confirm the expected sequence. Additional tests may include amino acid analysis and water content determination. Results are only comparable when the same column, gradient, and detection settings are used.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
=== Physicochemical factors affecting carbon nanotube toxicity === Numerous studies have identified key physicochemical properties of carbon nanotubes (CNTs) that influence their biological interactions and toxicological profiles in both in vitro and in vivo systems: Aspect ratio, length, and rigidity: Long and rigid CNTs exhibit increased biopersistence and are strongly associated with fibrogenesis, through the activation of the Smad2/3 and ERK1/2 signaling pathways. Their high aspect ratio and fiber-like morphology, reminiscent of asbestos, can impair macrophage-mediated clearance, and induce inflammation, fibrotic tissue remodeling, granuloma formation, and even DNA damage. Multi-walled carbon nanotubes (MWCNTs) with lengths ranging from approximately 0.5 to 10 μm have been implicated in severe pulmonary conditions, including asbestosis-like fibrosis and mesothelioma. Similarly, single-walled carbon nanotubes (SWCNTs) exceeding 10 μm in length can induce granulomatous lesions. In contrast, shorter SWCNTs—particularly those under 300 nm and well-dispersed—are more readily cleared from the body via renal and biliary excretion pathways. These shorter, purified SWCNTs have demonstrated significantly reduced inflammatory and cytotoxic responses and, to date, lack conclusive evidence of carcinogenicity. Aggregation state: The aggregation state of CNTs refers to their propensity to cluster into bundles or agglomerates, primarily driven by van der Waals forces and electrostatic interactions.
Cyclic amines—Cyclic amines are either secondary or tertiary amines. Examples of cyclic amines include the 3-membered ring aziridine and the six-membered ring piperidine. N-methylpiperidine and N-phenylpiperidine are examples of cyclic tertiary amines.
== Principle == An HID connected to a gas chromatograph (GC) has the great advantage to use helium as both the carrier gas and the ionization gas. An HID is an ion detector which uses a radioactive source, typically β-emitters, to create metastable helium species. The radioactive source ionizes helium atoms by bombarding them with emissions. The metastable helium species have an energy of up to 19.8 eV. These metastable helium species can ionize all compounds with the exception of neon which has a greater ionization potential of 21.56 eV. As components elute from the GC's column they collide with the metastable helium ions, which then ionize the components. The ions produce an electric current, which is the signal output of the detector. The greater the concentration of the component, the more ions are produced, and the greater the current.
Sources: en.wikipedia.org
=== Cardiovascular health === Matrix Gla protein is a vitamin K-dependent protein found in bone, but also in soft tissues such as arteries, where it appears to function as an anti-calcification protein. In animal studies, animals that lack the gene for MGP exhibit calcification of arteries and other soft tissues. In humans, Keutel syndrome is a rare recessive genetic disorder associated with abnormalities in the gene coding for MGP and characterized by abnormal diffuse cartilage calcification. These observations led to a theory that in humans, inadequately carboxylated MGP, due to low dietary intake of the vitamin, could result in increased risk of arterial calcification and coronary heart disease. In meta-analyses of population studies, low intake of vitamin K was associated with inactive MGP, arterial calcification and arterial stiffness. Lower dietary intakes of vitamin K1 and vitamin K2 were also associated with higher coronary heart disease. When blood concentration of circulating vitamin K1 was assessed there was an increased risk in all cause mortality linked to low concentration. In contrast to these population studies, a review of randomized trials using supplementation with either vitamin K1 or vitamin K2 reported no role in mitigating vascular calcification or reducing arterial stiffness. The trials were too short to assess any impact on coronary heart disease or mortality.
The four substrates of this enzyme are anthranilic acid, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are catechol, carbon dioxide, oxidised NAD+, and ammonia. The enzyme can also use nicotinamide adenine dinucleotide phosphate as a cofactor. This enzyme is an oxidoreductase which uses molecular oxygen as oxidant and incorporates its atoms into the product. The systematic name of this enzyme class is anthranilate,NAD(P)H:oxygen oxidoreductase (1,2-hydroxylating, deaminating, decarboxylating). Other names in common use include anthranilate hydroxylase, anthranilic hydroxylase, and anthranilic acid hydroxylase. It participates in three metabolic pathways: benzoate degradation via hydroxylation, carbazole degradation, and nitrogen metabolism. It requires ferrous iron.
Energy of about 6 MeV provided by the incident neutron was necessary to overcome this barrier and cause the nucleus to fission. According to John Lilley, "The energy required to overcome the barrier to fission is called the activation energy or fission barrier and is about 6 MeV for A ≈ 240. It is found that the activation energy decreases as A increases. Eventually, a point is reached where activation energy disappears altogether...it would undergo very rapid spontaneous fission." Maria Goeppert Mayer later proposed the nuclear shell model for the nucleus. The nuclides that can sustain a fission chain reaction are suitable for use as nuclear fuels. The most common nuclear fuels are 235U (the isotope of uranium with mass number 235 and of use in nuclear reactors) and 239Pu (the isotope of plutonium with mass number 239). These fuels break apart into a bimodal range of chemical elements with atomic masses centering near 95 and 135 daltons (fission products). Most nuclear fuels undergo spontaneous fission only very slowly, decaying instead mainly via an alpha-beta decay chain over periods of millennia to eons. In a nuclear reactor or nuclear weapon, the overwhelming majority of fission events are induced by bombardment with another particle, a neutron, which is itself produced by prior fission events. Fissionable isotopes such as uranium-238 require additional energy provided by fast neutrons (such as those produced by nuclear fusion in thermonuclear weapons).
On 21 October 2009 Becker became the first woman ever to be elected to the vice presidency of the University of Giessen, serving her three-year term from 1 November 2009 to 31 October 2012. Since 2014, Becker has been the coordinator of DFG Priority Program 1710, "Dynamics of Thiol-based Redox Switches in Cellular Physiology." Since 2018 she has been the coordinator of the LOEWE Center DRUID (Novel Drug Targets against Poverty-related and Neglected Tropical Infectious Diseases) as part of the Hessian State initiative to fund academic-economic excellence (LandesOffensive zur Entwicklung Wissenschaftlich-ökonomischer Exzellenz - LOEWE). On 3 July 2019 Becker was elected as president of the German Research Foundation, thereby becoming the first female to hold this post. In the year-long selection process, she won over Wolfgang Marquardt and Dorothea Wagner. She had been vice president of the German Research Foundation since 2014.
Sources: en.wikipedia.org
It is not approved for human use in the United States or the European Union. Clinical material has been studied in a small number of early trials, mainly for inflammatory bowel conditions, and the compound remains investigational. Regulators treat marketed products as unapproved rather than as authorized drugs.
The peptide was named after a protein fraction found in human gastric juice, and the shorter form was called body protection compound. That phrase was shortened to the abbreviation BPC. The number 157 refers to a laboratory designation used in the original isolation work.
Its sequence corresponds to a segment of a protein present in gastric secretions, but the material supplied for research is made synthetically. No commercial product is purified from human or animal tissue. The synthetic route is used because it gives a defined chain length and a reproducible sequence.
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.